CVRx, Inc. (NASDAQ: CVRX) has appointed John Landry as its new Chief Financial Officer. Landry will join the commercial-stage medical device company on October 12, 2026, succeeding Jared Oasheim.

Landry assumes the CFO role the day after the company files its Form 10-Q for the quarter ending September 30, 2026. Oasheim will remain with CVRx during a transition period consistent with his previously disclosed agreement.

Leadership Transition

Kevin Hykes, President and CEO of CVRx, stated that Landry brings significant commercial and capital markets experience. Hykes noted that Landry’s background in driving growth while managing expenses is relevant as CVRx scales its Barostim therapy for heart failure patients.

Hykes thanked Oasheim for his contributions since 2015, highlighting his role in leading the company through its initial public offering and building its financial foundation.

Candidate Profile

Landry currently serves as CFO of Nyxoah SA (Euronext Brussels/NASDAQ: NYXH). In that role, he raised several rounds of capital and drove operational efficiencies to fund U.S. commercial expansion.

Prior to Nyxoah, Landry spent 12 years at Vapotherm, Inc. (NYSE: VAPO), most recently as Senior Vice President and CFO. He led Vapotherm’s IPO and built its finance, investor relations, and public company reporting functions. Earlier roles include positions at Salient Surgical Technologies, Bottomline Technologies, Hussey Seating Company, and Coopers & Lybrand.

Landry holds a B.S. in Accountancy from Bentley College, is an inactive CPA, and serves on the board of Liberate Medical, Inc.

Strategic Focus

Landry cited the positive impact of Barostim on patients’ lives as a key draw for the role. Barostim is the first FDA-approved medical technology using neuromodulation to improve symptoms in heart failure patients. It delivers electrical pulses to baroreceptors in the carotid artery wall to restore autonomic nervous system balance.

The device holds FDA Breakthrough Device designation and CE Mark approval for heart failure and resistant hypertension in the European Economic Area.

Hagens Berman has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential securities law violations after the company’s shares dropped 59% on August 7, 2026.

The legal review follows a series of operational setbacks disclosed after market close on August 6, including a U.S. Department of Justice Civil Investigative Demand (CID), significant revenue guidance cuts, and the abrupt termination of Chief Revenue Officer Robert John on August 10, 2026.

Investigation Focus

The firm is examining whether CVRx misled investors about the health of its commercial sales force and Medicare Advantage reimbursement rates. Partner Reed Kathrein stated the investigation will assess the connection between the DOJ CID and the CRO’s dismissal.

Key issues under scrutiny include:

• A CID received on May 14, 2026, investigating potential false claims related to the marketing of Barostim, an implantable neuromodulation device for heart failure.
• Allegations of kickbacks to healthcare providers and submission of false information to government health programs.
• Discrepancies between earlier assurances of a "largely complete" sales force transformation and subsequent disclosures of sequential flat growth in sales territories and high turnover.

Operational Headwinds

CVRx reported severe disruptions in its primary revenue drivers. The company’s main Medicare Advantage payer reduced initial approval rates from 80% to just 25% within 30 days, citing increased denials.

What the Numbers Show

The divergence between CVRx’s earlier market positioning and its recent disclosures highlights a sharp reversal in commercial execution. The firm previously anchored its growth strategy on a $10.5 billion market opportunity with less than 1% penetration and a transformed sales force. The simultaneous collapse of Medicare approvals to 25% and the admission of sales force strain suggest the earlier "complete" transformation claims may not have reflected underlying operational realities at the time of disclosure.

Investor Action

Investors who suffered losses are encouraged to submit their details to evaluate legal rights. Whistleblowers with non-public information may also contact the firm regarding potential SEC whistleblower program rewards.